Loading...
Chemed delivered solid Q1 2025 results, with revenue rising to $646.9M and adjusted EPS reaching $5.63. Growth was driven by VITAS Healthcare, bolstered by the recent Covenant Health acquisition, while Roto-Rooter remained relatively flat.
Updated 2025 earnings guidance will be provided with the Q2 release in June.
Analyze how earnings announcements historically affect stock price performance